TACHYON THERAPEUTICS
Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer. The company is currently conducting Phase 1 clinical research in patients with advanced cancer to assess the safety, pharmacokinetics, and anti-tumor effectiveness of TACH101. The programs will be advanced in a timely, innovative, high-quality, and scientifically sound manner.
TACHYON THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2019-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.tachyontx.com
Total Employee:
1+
Status:
Active
Contact:
(628) 216-5899
Email Addresses:
[email protected]
Total Funding:
18.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics WordPress Content Delivery Network Global Site Tag ReCAPTCHA
Similar Organizations
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Clade Therapeutics
Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
Novasenta
Novasenta develops treatments to transform the lives of patients with cancer.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Rondo Therapeutics
Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
Tr1x
Tr1x develops universal cellular therapies intended for the treatment of autoimmune disorders.
Current Advisors List
Current Employees Featured
Founder
Investors List
Veblen Ventures
Veblen Ventures investment in Series A - Tachyon Therapeutics
Khosla Ventures
Khosla Ventures investment in Series A - Tachyon Therapeutics
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Tachyon Therapeutics
Red Tree Venture Capital
Red Tree Venture Capital investment in Series A - Tachyon Therapeutics
Official Site Inspections
http://www.tachyontx.com Semrush global rank: 16.13 M Semrush visits lastest month: 1
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Tachyon Therapeutics"
About | Founded by experts in cancer biology and tumorigenesis
Tachyon completed seed funding, established a fully operational organization, and began IND-enabling studies for its KDM4 inhibitor, TACH101. 2021. Tachyon expanded its pipeline and …See details»
Tachyon Management Team
Tachyon operates with a dedicated internal core development team and a world-class external network of expertise. We enlist the support of leading experts in their field, from pharmacology to manufacturing, and from science to clinical to …See details»
Tachyon Therapeutics - Crunchbase Company Profile
Organization. Tachyon Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone Number (628) 216-5899; Tachyon …See details»
Tachyon Therapeutics Inc. Company Profile - Dun & Bradstreet
Tachyon Therapeutics Inc. Company Profile | Houston, TX | Competitors, Financials & Contacts - Dun & BradstreetSee details»
Tachyon Therapeutics Inc. in Houston, TX - (832) 952-0829 - Profile
Tachyon Therapeutics Inc. is in the Biotechnical Research, Commercial business. View competitors, revenue, employees, website and phone number.See details»
Tachyon Transport LLC in Houston, TX - (713) 410-9540 - Profile
Tachyon Transport LLC is in the Transportation Services, nec business. View competitors, revenue, employees, website and phone number.See details»
Tachyon Therapeutics - Overview, News & Similar companies
Who is Tachyon Therapeutics. Tachyon Therapeutics, Inc. develops first-in-class therapeutics against novel targets from previously unexplored cancer dysregulation pathways to p ropel …See details»
Investors - Tachyon
Find us Tachyon Therapeutics, Inc. 1160 Battery Street East, Suite 100 | San Francisco, CA 94111 24 Greenway Plaza, Suite 1800 | Houston, TX 77046. contact info ...See details»
Tachyon Therapeutics - ContactOut
Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core …See details»
Tachyon - Company Profile - Tracxn
Dec 5, 2024 Tachyon - Developer of therapeutics for cancer. Raised a total funding of $11.6M over 2 rounds from 4 investors. Tachyon has 2860 competitors.See details»
AbCellera Biologics Inc. - Tachyon and AbCellera Collaborate to …
Aug 3, 2021 Tachyon operates with a dedicated internal core development team and a virtual external network of expertise to achieve one goal – advance development of promising drug …See details»
Tachyon - Overview, News & Similar companies | ZoomInfo.com
Feb 28, 2023 Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- …See details»
Tachyon Announces Financing and Start of Clinical Study of First …
Mar 1, 2023 SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing …See details»
Tachyon Board of Directors
Jonathan MacQuitty, PhD. Chairman. Dr. MacQuitty has over three decades of experience in the life science and healthcare sectors. He currently serves as the Chairman of the Board of …See details»
Tachyon Receives IND Clearance from FDA to Develop
Aug 24, 2022 Contacts. Investor & Company Contact: Frank Perabo, Chief Executive Officer, +1(832)952-0829, [email protected] Media Contact: Jessica Yingling, Ph.D., Little Dog ...See details»
Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study …
Mar 1, 2023 Contacts. Investor & Company Contact: Frank Perabo, Chief Executive Officer, +1(832)952-0829, [email protected] Media Contact: Jessica Yingling, Ph.D., Little Dog ...See details»
Tachyon Receives Funding from CIRM for a Phase 1 Clinical
Mar 1, 2023 SAN FRANCISCO & HOUSTON--(BUSINESS WIRE)-- Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private, clinical-stage biotechnology company developing …See details»
Cyclyx names new CEO, plans office in Houston - Houston …
2 hours ago The recycling joint venture between Exxon, LyondellBasell and Agilyx is also developing its first advanced recycling plant in Houston. Cyclyx International LLC — a joint …See details»
Commitment to Diversity - Tachyon
We are committed to enrolling a diverse population in our clinical trial – inclusive of race, ethnicity, gender, age, sexual orientation, disability, location and socioeconomic status. A diverse …See details»
Events and Presentations - Tachyon
Oct 11-15, 2023. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Go to >>See details»